Search
for
Sort by
Research 241–270 of 772
- Could baricitinib treat frontal fibrosing alopecia and facial papules?
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Poster Presentations
- Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders
- Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
- New therapies for alopecia areata
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
- Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Ritlecitinib in severe alopecia areata: a profile of its use
- Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata